Krishnansu S. Tewari
克里什纳苏·泰瓦里
MD
Professor and Division Director, Gynecologic Oncology; Director, Fellowship Program妇科肿瘤学部主任教授；研究员计划主任
👥Biography 个人简介
Krishnansu S. Tewari, MD is Professor and Division Director of Gynecologic Oncology at UC Irvine, best known for leading the pivotal GOG 240 trial that first demonstrated an overall survival benefit for the addition of bevacizumab to chemotherapy in persistent, recurrent, or metastatic cervical cancer—a landmark result that changed the global standard of care for advanced cervical cancer for the first time in decades. Dr. Tewari is also a principal investigator for immunotherapy trials in cervical cancer and has made foundational contributions to understanding tumor angiogenesis in gynecologic cancers.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
GOG 240 Trial — Bevacizumab in Cervical Cancer
Led the GOG 240 phase III trial demonstrating that adding bevacizumab to cisplatin-based chemotherapy improved overall survival from 13.3 to 17.0 months in advanced cervical cancer, resulting in FDA approval of bevacizumab for this indication.
Immunotherapy Combinations in Cervical Cancer
Led early-phase trials integrating PD-1/PD-L1 checkpoint inhibitors with anti-angiogenic therapy in recurrent cervical cancer, contributing data that supported the approval of pembrolizumab in cervical cancer.
Translational Research in Tumor Angiogenesis
Conducted translational studies on VEGF expression, microvessel density, and angiogenic pathway activation in cervical tumors, defining correlative biomarkers for anti-angiogenic treatment benefit.
Representative Works 代表性著作
Bevacizumab for Advanced Cervical Cancer: Final Overall Survival and Adverse Event Analysis of a Randomised, Controlled, Open-Label, Phase 3 Trial (Gynecologic Oncology Group 240)
The Lancet (2017)
Definitive analysis of GOG 240 confirming sustained OS benefit of bevacizumab plus chemotherapy in advanced cervical cancer.
Angiogenesis as a Strategic Target for Treating Uterine Cervical Cancer
Gynecologic Oncology (2015)
Comprehensive translational review linking tumor angiogenesis biology to clinical efficacy of bevacizumab in cervical cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 克里什纳苏·泰瓦里 的研究动态
Follow Krishnansu S. Tewari's research updates
留下邮箱，当我们发布与 Krishnansu S. Tewari（University of California, Irvine, School of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment